Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrence-Reference-Cited by-同舟云学术

Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrence

Published:2024-05-10 Issue:6 Volume:8 Page:
ISSN:2471-254X
Container-title:Hepatology Communications
language:en
Short-container-title:

Author:

Sanyal Arun J.¹,Kowdley Kris V.²,Reau Nancy S.³,Pyrsopoulos Nikolaos T.⁴,Allen Christopher⁵,Heimanson Zeev⁵,Bajaj Jasmohan S.¹⁶

Affiliation:

1. Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University, Richmond, Virginia, USA

2. Department of Gastroenterology and Hepatology, Elson Floyd College of Medicine, Spokane, Washington, USA

3. Department of Medicine, Rush University, Chicago, Illinois, USA

4. Rutgers New Jersey Medical School, Newark, New Jersey, USA

5. Salix Pharmaceuticals, Bridgewater, New Jersey, USA

6. Central Virginia Veterans Healthcare System, Richmond, Virginia, USA

Abstract

Background: The aim was to examine rifaximin plus lactulose efficacy in patients with cirrhosis at a risk of developing overt HE who were stratified by important baseline characteristics such as comorbid ascites or diabetes. Methods: Pooled post hoc subgroup analysis of adults receiving rifaximin 550 mg twice daily plus lactulose or lactulose alone for 6 months in a phase 3 randomized, double-blind trial and a phase 4 open-label trial was conducted. Results and Conclusion: Rifaximin plus lactulose was more efficacious than lactulose alone for reducing the risk of overt HE recurrence and HE-related hospitalization in adults grouped by select baseline disease characteristics.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference9 articles.

1. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies;D’Amico;J Hepatol,2006

2. Liver cirrhosis;Tsochatzis;Lancet,2014

3. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver;Vilstrup;Hepatology,2014

4. A risk score to predict the development of hepatic encephalopathy in a population-based cohort of patients with cirrhosis;Tapper;Hepatology,2018

5. Diabetes mellitus—Risk factor and potential future target for hepatic encephalopathy in patients with liver cirrhosis?;Gairing;Metab Brain Dis,2023

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Erratum: Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrencey;Hepatology Communications;2024-06-27